Emcure Pharmaceuticals
add_icon

Emcure Pharmaceuticals

1,430.90
+29.10
(2.08%)
Market Cap
₹27,124.83 Cr
PE Ratio
32.46
Volume
3,11,922.00
Day High - Low
₹1,445.30 - ₹1,388.10
52W High-Low
₹1,519.90 - ₹889.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
27,124.83 Cr
EPS
36.43
PB Ratio
5.61
Book Value
250.17
EBITDA
1,541.60
Dividend Yield
0.21 %
Industry
Healthcare
Return on Equity
15.24
Debt to Equity
0.45
Analyst Rating and Forecast
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+83.33 %
+83.33 %
Hold
Hold+16.67 %
+16.67 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Emcure Pharmaceuticals receives No Action Indicated (NAI) classification from USFDA for its Kadu, Gujarat manufacturing facility following inspection completion.
positive
Emcure Pharmaceuticals becomes first Indian company to launch Novo Nordisk's semaglutide injection for weight control, available in five strengths with starting price ₹8,790 per month.
neutral
Emcure Pharmaceuticals allotted 7,700 equity shares to employees under its ESOP scheme on December 16, 2025, increasing paid-up share capital to ₹189.57 crores.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,728.00
#1 4,14,605.08
39.37
#1 54,729.00
9.71
#1 10,980
2.89
42.10
6,392.50
1,69,700.79
67.76
9,712.00
18.67
2,191
35.10
48.20
3,885.30
1,31,496.21
60.85
11,539.40
6.99
1,911
30.46
67.66
1,511.60
1,22,102.78
22.30
28,409.50
7.12
5,291
3.71
51.10
1,256.10
1,04,837.92
#1 18.24
33,741.20
16.73
5,725
-0.38
45.31
2,105.30
96,169.85
22.10
22,909.50
13.74
3,306
#1 72.75
56.06
916.90
92,261.59
18.30
23,511.00
18.55
4,615
34.60
45.37
2,202.70
90,928.57
50.34
12,744.20
#1 20.90
2,007
-21.05
50.55
1,215.40
70,590.63
20.25
32,345.60
9.43
3,484
3.81
56.45
5,592.50
66,866.73
27.11
13,458.30
3.70
2,216
10.98
50.91
Growth Rate
Revenue Growth
18.67 %
Net Income Growth
34.10 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
0.99 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,959
2,121
2,104
2,273
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,601
1,724
1,687
1,794
EBITDA
311
327
316
323
360
417
359
397
417
479
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
20 %
21 %
Depreciation
67
70
84
91
94
97
97
97
100
105
Interest
52
59
61
66
59
46
32
39
27
33
Profit Before Tax
191
198
171
167
207
273
230
261
291
341
Tax
50
52
51
46
55
72
74
63
76
90
Net Profit
141
146
120
121
153
202
156
197
215
251
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97
10.92
12.85

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,197
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
177
Investments
0
0
0
0
25
25
318
95
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
4,763
Total Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,642
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-700
32
259
42
134
219
-58
Investing Activities
-409
-168
-257
-575
-468
-715
-96
Operating Activities
444
500
704
768
747
1,097
852
Financing Activities
-735
-301
-189
-152
-145
-164
-814

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
77.91 %
77.88 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
2.86 %
3.29 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
2.84 %
4.37 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
5.95 %
6.24 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
10.44 %
8.22 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671
1,33,549
1,26,169

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.21 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,406.40 1,444.25
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,345.75 1,249.80
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,036.35 1,073.60
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 1,405.55 1,421.25
14 Aug 2025 DIVIDEND Dividend
₹ 3.00 /share
14 Aug 2025 1,073.60 1,453.80
28 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Aug 2025 1,408.15 1,468.60
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 1,318.00 1,426.60

Announcements

Update On US FDA Inspection At Our Manufacturing Facility Located At Kadu Surendranagar Gujarat India.9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 22, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 01, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Search And Seizure/ Inspection Operation Conducted By The Goods & Service Tax Department Mumbai Maharashtra.Nov 27, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 19, 2025
Intimation Of Receipt Of No-Objection Letter For Reclassification Of Shareholding From Promoter And Promoter Group Category To Public Category In Accordance With Regulation 31A Of The Securities And Exchange Board Of India (Listing Obligations And DisclosNov 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Board Meeting Outcome for Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Half-Year Ended September 30 2025Nov 11, 2025
Unaudited Financial Results For The Quarter And Half-Year Ended September 30 2025Nov 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 03, 2025
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30 2025Nov 03, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At Our Manufacturing Facility Located At Kadu Surendranagar Gujarat India.Oct 10, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Intimation Of Withdrawal Of Re-Classification Application Under Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 07, 2025
Intimation Of Change In Email Address Of MUFG Intime India Private Limited Registrar And Share Transfer Agent Of The Company.Oct 06, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 03, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 29, 2025
Closure of Trading WindowSep 26, 2025
Update On Re-Appointment Of Dr. Mukund Gurjar As A Whole-Time Director And Appointment Of Secretarial Auditor Of The Company.Aug 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Intimation Under Regulation 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 About Dispatch Of Letters To The Members Whose E-Mail Addresses Are Not Registered With The Company/ Depository Participants.Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Outcome Of The Board Meeting Held On August 07 2025 To Approve The Unaudited Financial Results (Consolidated And Standalone) For The Quarter Ended June 30 2025Aug 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 03, 2025
Intimation Of Notice Of The 44Th Annual General Meeting Of Emcure Pharmaceuticals Limited To Be Held On Thursday August 28 2025Aug 02, 2025
Reg. 34 (1) Annual Report.Aug 02, 2025
Intimation Of The 44Th AGM And Record Date For Final Dividend For The Financial Year Ended March 31 2025.Aug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025.Jul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 14, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At Our Manufacturing Facility (Oncology) Located At Sanand Ahmedabad Gujarat India.Jul 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 04, 2025
Closure of Trading WindowJun 25, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Submission Of Application For Seeking Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 25, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 25, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Multi Cap Fund Direct-Growth
0.57%
1031343
0.30%
0.30%
Nippon India ELSS Tax Saver Fund Direct-Growth
0.57%
623160
0.57%
0.57%
HSBC Small Cap Fund Direct-Growth
0.50%
570564
0.50%
0.50%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-445701
-0.91%
-0.92%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
1.22%
294339
0.33%
0.33%
Nippon India Pharma Fund Direct-Growth
1.24%
269987
0.50%
0.50%
Bandhan Flexi Cap Fund Direct-Growth
0.37%
200000
0.37%
0.37%
Bandhan Multi Cap Fund Direct-Growth
0.56%
115000
0.56%
0.56%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.42%
75000
0.42%
0.42%
Aditya Birla Sun Life Bal Bhavishya Yojna Direct-Growth
1.52%
29433
0.41%
0.39%
Groww Multicap Fund Direct-Growth
0.00%
-27416
-1.54%
-0.94%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
0.57%
24528
0.57%
0.57%
Axis Equity Savings Fund Direct-Growth
0.39%
19900
0.31%
0.31%
Motilal Oswal Quant Fund Direct-Growth
0.00%
-11248
-1.01%
-1.03%
DSP Aggressive Hybrid Fund Direct-Growth
0.57%
-9370
0.02%
0.03%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
1.47%
8758
0.28%
0.11%
Groww Aggressive Hybrid Fund Direct - Growth
0.00%
-7101
-1.87%
-0.95%
Groww Value Fund Direct-Growth
0.00%
-6713
-1.35%
-1.38%
DSP Healthcare Fund Direct - Growth
1.73%
-5202
0.08%
0.09%
Axis Business Cycles Fund Direct-Growth
0.00%
-4725
-0.03%
-0.93%
DSP Top 100 Equity Direct Plan-Growth
0.58%
-4566
0.01%
0.01%
DSP Multicap Fund Direct - Growth
0.65%
-4275
0.02%
0.01%
Groww Large Cap Fund Direct-Growth
0.00%
-4160
-0.42%
0.00%
DSP Equity Savings Fund Direct-Growth
0.32%
-3812
0.01%
0.02%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.18%
642
0.02%
0.02%

Technical Indicators

RSI(14)
Neutral
51.31
ATR(14)
Volatile
44.42
STOCH(9,6)
Neutral
34.66
STOCH RSI(14)
Neutral
20.49
MACD(12,26)
Bearish
-2.66
ADX(14)
Weak Trend
24.83
UO(9)
Bearish
53.35
ROC(12)
Uptrend And Accelerating
0.46
WillR(14)
Neutral
-59.47

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(1 Years, 23 days)
Chairperson NameBerjis M Desai